Regulatory milestones

AB Science S.A. (Euronext:AB) fell €4 (21%) to €15 on Friday after EMA's CHMP issued a negative opinion recommending against approval of an MAA for Masican masitinib to treat gastrointestinal stromal tumors (GIST) that cannot be removed surgically or have progressed following treatment with Gleevec imatinib.